Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin-releasing hormone agonist on ovarian cancer cell growth

Fertility and Sterility

Volumn 67, Issue 5, 1997, Pages 870-876

  Ho, Minh N ^a,b   Delgado, Cynthia H ^a   Owens, Garrison A ^a   Steller, Michael A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Building 10 ^*  (United States)

Author keywords

biphasic; IGF II; ovarian cancer; tryptorelin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GONADORELIN; GONADORELIN AGONIST; MESSENGER RNA; RIBONUCLEASE; SOMATOMEDIN B; TRIPTORELIN;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COLORIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE EXPRESSION; HORMONE BINDING; HUMAN; HUMAN CELL; MITOGENESIS; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA TRANSCRIPTION;

EID: 0030890171     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)81399-4     Document Type: Article

References (25)

1. Yano T, Pinski J, Radulovic S, Schally AV. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1994;91:1701-5.
2. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993;53:5439-6.
3. Kakar S, Grizzle W, Neil J. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 1994; 106:145-9.
4. Irmer G, Ortmann O, Kakar S, Neil J, Schulz KD, Emons G. Expression of the messenger RNAs for luteinizing hormonereleasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 1995;55:817-22.
5. Emons G, Brack C, Sturm R, Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinoma. Eur J Cancer Clin Oncol 1989;25:215-21.
6. Parmar H, Rustin G, Lightman SL, Phillips RH, Hanham IW, Schally AV. Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. Br Med J 1988;296:1229.
7. Manetta A, Gamboa-Vujicic G, Paredes P, Emma D, Liao S, Leong L, et al. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertil Steril 1995;63:282-7.
8. Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res 1992;52:6447-51.
9. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995;55:2463-9.
10. Yee D, Morales F, Hamilton T, Von Hoff D. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res 1991;51:5107-12.
11. Baserga R. IGF-1 receptor as the restriction point of the cell cycle. Ann NY Acad Sci 1992;663:154-7.
12. Steller MA, Delgado CH, Zou Z. Insulin-like growth factor-2 mediates epidermal growth factor induced mitogenesis in cervical cancer cells. Proc Natl Acad Sci USA 1995;92:11970-4.
13. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107:220-39.
14. Hernandez ER, Hurwitz A, Vera A, Pellicer A, Adashi EY, LeRoith D, et al. Expression of the genes encoding the insulin-like growth factors and their receptors in the human ovary [published erratum appears in J Clin Endocrinol Metab 1993;76:1343]. J Clin Endocrinol Metab 1992; 74:419-25.
15. Lowe WL Jr, Roberts CT Jr, LeRoith D, Rojeski MT, Merimee TJ, Fui ST, et al. Insulin-like growth factor-II in nonislet cell tumors associated with hypoglycemia: increased levels of messenger ribonucleic acid. J Clin Endocrinol Metab 1989; 69:1153-9.
16. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 1980;36:53-88.
17. Imai A, Ohno T, lida K, Fuseya T, Furui T, Tamaya T. Gonad-otropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer 1994; 74:2555-61.
18. Imai A, lida K, Tamaya T. Gonadotropin-releasing hormone has a biphasic action on aromatase activity through protein kinase C in granulosa cells. Int J Fertil Menopausal Stud 1993;38:50-6.
19. Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 1993;69:756-60.
20. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20.
21. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994;369:414-8.
22. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994;9:1364-79.
23. Kleinman D, Roberts CT Jr, LeRoith D, Schally AV, Levy J, Sharoni Y. Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75. Regul Pept 1993;48:91-8.
24. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT Jr, LeRoith D, et al. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 1993;77:963-8.
25. Stojilkovic SS, Catt KJ. Expression and signal transduction pathways of gonadotropin-releasing hormone receptors. Recent Prog Horm Res 1995;50:161-205.